La chaîne d'options affiche les données clés des options sur actions de RxSight à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour RxSight..

RxSight (NASDAQ:RXST) Stock, Chaîne d'Options

RXSIGHT INC

RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

RxSight Inc

News

MRNA

Moderna Receives Full FDA Approval for COVID-19 Vaccine, Spikevax, In Children Aged 6 Months Through 11 Years At Increased Risk For COVID-19 Disease

Macro Economic Events

Econ #s

Economics

USA Continuing Jobless Claims 1,965K Vs 1,980K Est.

Goldman Sachs analyst James Schneider initiates coverage on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Neutral rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

AMKR

Goldman Sachs Initiates Coverage On Amkor Tech with Neutral Rating, Announces Price Target of $20

US Initial Jobless Claims 227K vs 236K Est.

Goldman Sachs analyst James Sheehan initiates coverage on GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral rating and announces Price Target of $40.

Goldman Sachs Initiates Coverage On GLOBALFOUNDRIES with Neutral Rating, Announces Price Target of $40

WIIM

HTOO

Fusion Fuel Green shares are trading lower after the company announced a 1-for-35 reverse stock split to regain Nasdaq minimum bid price rule compliance.

Goldman Sachs analyst James Sheehan initiates coverage on Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Western Digital with Neutral Rating, Announces Price Target of $130

D. Boral Capital analyst Jesse Sobelson maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $15 price target.

EVTL

D. Boral Capital Maintains Buy on Vertical Aerospace, Maintains $15 Price Target

PASG

Passage Bio shares are trading lower after the company announced a 1-for-20 reverse stock split.

Goldman Sachs analyst James Sheehan initiates coverage on Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Micron Technology with Neutral Rating, Announces Price Target of $130

KLTO

Klotho Neurosciences shares are trading higher after the company announced the FDA has awarded orphan drug status for KLTO-202 for novel gene therapy in amyotrophic lateral sclerosis patients.

Goldman Sachs analyst James Schneider initiates coverage on Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral rating and announces Price Target of $85.

ENTG

Goldman Sachs Initiates Coverage On Entegris with Neutral Rating, Announces Price Target of $85

As JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) prepares to unveil its second-quarter earnings on July 15, the financial world is bracing for a significant shift that reflects broader economic trends. Over the past year, rising interest rates and inflationary pressures have squeezed borrowers and heightened market volatility, factors that are expected to dampen <a href="https://www.benzinga.com/quote/JPM/earnings">the bank&#8217;s profits.</a>
Analysts expect the company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Wednesday, Truist Securities analyst John McDonald maintained a Hold rating on JPMorgan and raised the price target from $280 to $290.
With the recent buzz around JPMorgan, some investors may be eyeing potential gains from the company's dividends. As of now, JPMorgan offers an annual dividend yield of 1.98%, which is a quarterly dividend amount of $1.40 per share ($5.60 a year).
To figure out how to earn $500 monthly from JPMorgan, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by JPMorgan's $5.60 dividend: $6,000 / $5.60 = 1,071 shares.
So, an investor would need to own approximately $303,264 worth of JPMorgan, or 1,071 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $5.60 = 214 shares, or $60,596 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
JPM Price Action: Shares of JPMorgan gained by 0.1% to close at $283.16 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo: Rokas Tenys/Shutterstock

Earnings

Long Ideas

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy and maintains $14 price target.

NRSN

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

SAFX

XCF Global shares are trading higher after the company announced it will invest $1 billion in U.S. SAF plants.

Goldman Sachs analyst James Schneider initiates coverage on KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Neutral rating and announces Price Target of $980.

KLAC

Goldman Sachs Initiates Coverage On KLA with Neutral Rating, Announces Price Target of $980

DALN

DallasNews shares are trading higher after the company announced Hearst will acquire it for $14 per share.

KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.82) by 20.58 percent. This is a 2.94 percent increase over losses of $(1.02) per share from the same period last year.

Earnings Misses

KALV

KalVista Pharma Q4 EPS $(0.99) Misses $(0.82) Estimate

&nbsp;K Wave Media Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kwm#NASDAQ">KWM</a>) ("K Wave" or the "Company"), the first Nasdaq-listed public company to integrate Korean cultural content with a Bitcoin-focused corporate treasury model, today announced entering into
&nbsp;K Wave Media Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) ("K Wave" or the "Company"), the first Nasdaq-listed public company to integrate Korean cultural content with a Bitcoin-focused corporate treasury model, today announced entering into a convertible note agreement with Anson Funds where Anson agreed to provide up to $500 million in financing under which KWM will allocate minimum 80% of the net proceeds toward purchase of BTC. The first tranche will be the issuance and sale of $15 million in senior secured convertible notes and warrants to Anson Investments Master Fund, LP, and Anson East Master Fund LP pursuant to a securities purchase agreement.
This follows the previously announced $500 million Standby Equity Purchase Agreement (SEPA) with Bitcoin Strategic Reserve, bringing the Company's total capital capacity for its treasury initiative to $1 billion.
With execution underway, KWM has completed its initial acquisition of "88" BTC. "88", widely regarded as a symbol of fortune and success in Asian culture, demonstrates firm conviction in Bitcoin as a superior long-term investment. The Company intends to scale its holdings of Bitcoin aggressively and transparently, aligning itself with the monetary principles of Bitcoin and the growing global movement of on-chain corporate reserves.
"We believe that this financing structure positions us to execute one of the most ambitious corporate Bitcoin accumulation strategies in the world," said Ted Kim, CEO of K Wave Media. "Our objective is clear: to scale our holdings toward 10,000 Bitcoin as soon as possible while maintaining strong investor alignment and full transparency in treasury reporting. At the same time, our existing K-content businesses stand to benefit from this BTC-driven treasury strategy as we actively explore innovative ways for global fans to engage with, consume, and even invest in our premium movies and dramas using Bitcoin."
Amin Nathoo, CEO of Anson, said, "We are excited to partner with K Wave and their impressive management team as they execute on both the K-content and Bitcoin treasury opportunities."
KWM's model combines capital markets sophistication with cultural resonance. By anchoring Bitcoin to a forward-looking media platform, the Company aims to create new pathways for investor participation and global engagement and be a leader in the Web3 economy.

Small Cap

Treasuries

K Wave Media Announces It Has Secured $1B Capital Capacity To Drive Bitcoin Treasury Strategy As Well As A $500M Convertible Note With Anson Funds

Cantor Fitzgerald analyst Brett Knoblauch maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Overweight and raises the price target from $21 to $23.

BTDR

Cantor Fitzgerald Maintains Overweight on Bitdeer Technologies, Raises Price Target to $23

Press Releases

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

Health Care

RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

RxSight, Inc. to Present at the Bank of America Healthcare Conference

RxSight, Inc. Reports First Quarter 2025 Financial Results

RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

Comments

RxSight

RxSight (RXST) Options

RxSight (NASDAQ:RXST) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL